Clinical Trials

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05849480 2026-03-24

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1/2 Recruiting

60 enrolled

Phase 2/3 Not yet recruiting

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT07437287 2026-02-27

CROCOBIL

160 enrolled

Biliary Tract Neoplasms

NCT07146646 2026-02-19

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

Phase 2 Recruiting

27 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Phase 1/2 Recruiting

258 enrolled

Biliary Tract Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

74 enrolled

GastrointestinalGynecologic

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03314935 2025-08-12

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Phase 1/2 Completed

149 enrolled 35 charts

Biliary Tract Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Phase 2 Not yet recruiting

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07025174 2025-06-17

SAIB

Phase 2 Recruiting

60 enrolled

Phase 3 Active not recruiting

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03478488 2025-05-29

KN035-BTC

480 enrolled

Biliary Tract Neoplasms

NCT06214572 2025-04-11

RUGB

Phase 2/3 Recruiting

249 enrolled

Phase 2/3 Not yet recruiting

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

206 enrolled

Phase 2 Not yet recruiting

Biliary Tract Neoplasms

NCT06502080 2024-07-17

RADITOP

128 enrolled

Biliary Tract Neoplasms

NCT05116891 2023-07-03

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Phase 1/2 Completed

40 enrolled

GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04796454 2022-06-01

PAMICC

Phase 2 Withdrawn

Biliary Tract Neoplasms

NCT03162510 2022-04-07

SOLAR

Phase 1 Completed

18 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT03111732 2021-12-03

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

11 enrolled 16 charts

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT03778593 2021-02-04

FOLFIRINOX for 2nd-line Treatment of BTC

34 enrolled

Biliary Tract Neoplasms

NCT01926236 2020-01-28

ABC06

Phase 3 Completed

162 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02350686 2019-05-20

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

67 enrolled

Biliary Tract Neoplasms

NCT00142480 2018-04-25

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

8 enrolled

Biliary Tract Neoplasms

NCT00955721 2018-01-03

A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Terminated

9 enrolled 7 charts

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02527824 2017-08-23

Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer

31 enrolled

Biliary Tract Neoplasms

NCT00361231 2017-02-07

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

35 enrolled 6 charts

Biliary Tract Neoplasms

NCT01572324 2017-01-04

Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas

37 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT01308840 2016-08-17

UGIH09067

31 enrolled 10 charts

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis

NCT01267344 2016-05-04

BTC

122 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT00881504 2014-10-20

A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma

Phase 2 Terminated

9 enrolled 7 charts

Biliary Tract Neoplasms

NCT01127555 2013-10-08

Salvage mFOLFOX in BTC After Failure of Gemcitabine

30 enrolled

Biliary Tract Neoplasms

NCT00338988 2012-08-01

Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

44 enrolled 5 charts

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT00174564 2012-02-17

EXIBIT: Oxaliplatin in Biliary Tract Cancer

67 enrolled

Biliary Tract Neoplasms

NCT01494363 2011-12-19

Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer

53 enrolled

Biliary Tract Neoplasms

NCT01234051 2011-12-12

Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer

53 enrolled

Biliary Tract Neoplasms

NCT01180153 2010-08-12

Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)

40 enrolled